Plixorafenib
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Plixorafenib
- Molecular weight
- 542.54
- Structure (SMILES)
- O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
- fore 8394
- FORE-8394
- fore8394
- FORE8394
- plixorafenib
- Plixorafenib
- plixorafenib [INN]
- PLIXORAFENIB [USAN]
- plixorafenib inn
- plixorafenib usan
- plx 8394
- Plx 8394
- PLX 8394 [WHO-DD]
- plx 8394 who dd
- Plx-8394
- plx8394
- PLX8394
- CAS registry numbers
- 1393466-87-9
- ChEMBL ID
- CHEMBL4303729
- InChIKey
- YYACLQUDUDXAPA-MRXNPFEDSA-N
- PubChem compound IDs
- 90116675
- FDA ingredient codes (UNII)
- J2L7Z273SG
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- plixorafenib
- Type
- Synthetic organic
- Drug name stem
- -rafenib
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Raf-1 proto-oncogene, serine/threonine kinase
- Gene symbol
- RAF1
- Protein identifier
- P04049
- Median affinity
- 7.64
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- B-Raf proto-oncogene, serine/threonine kinase
- Gene symbol
- BRAF
- Protein identifier
- P15056
- Median affinity
- 7.85
- Affinity units
- pIC50
- Mechanism
- Serine/threonine-protein kinase B-raf inhibitor
- Action type
- Inhibitor
- Target
- Serine/threonine-protein kinase B-raf
- Protein identifier
- P15056
Open Targets mechanisms
- Mechanism
- Serine/threonine-protein kinase B-raf inhibitor
- Action type
- Inhibitor
- Target
- Serine/threonine-protein kinase B-raf
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Melanoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Cholangiocarcinoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005221
- Subject identifier
- D018281
- Condition
- Leukemia, Hairy Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:1000956
- Subject identifier
- D007943
- Condition
- Histiocytosis
- Highest recorded phase
- 1
- Condition identifier
- HP:0100727
- Subject identifier
- D015614
- Condition
- Thyroid Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0002108
- Subject identifier
- D013964
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005575
- Subject identifier
- D015179
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000756
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 1
- Condition identifier
- EFO_0005221
- Highest recorded phase
- 1
- Condition identifier
- EFO_1000956
- Highest recorded phase
- 1
- Condition identifier
- HP_0100727
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002108
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002108
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005070
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005105
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018935
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0021042
- Highest recorded phase
- 1
- NCT02012231
- NCT02428712
- NCT05503797
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 2
- Polar surface area
- 120.94
- Calculated partition coefficient (ALogP)
- 4.11
- Calculated partition coefficient (XLogP)
- 2.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 7
- Heavy atoms
- 38
- Molecular formula
- C25H21F3N6O3S
- Monoisotopic mass
- 542.13479421
- Natural product
- No
- Recorded assays
- 331
- Active assays
- 60
- Confirmatory
- Other
- Screening
Related records
Trials (6)
- A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors
- A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.
- A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma
- Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot Study
- Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
In development for (10)
- Cancer Phase 2
- Cholangiocarcinoma Phase 1
- Colorectal cancer Phase 1
- Glioma Phase 1
- Hairy cell leukemia Phase 1
- Histiocytosis Phase 1
- Melanoma Phase 1
- Neoplasm Phase 2
- Non-small cell lung carcinoma Phase 1
- Thyroid cancer Phase 1